(5-氨基苯并[b]噻吩-2-基)-4-吗啉甲酮 | 832102-95-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: (5-氨基苯并[b]噻吩-2-基)-4-吗啉甲酮
• 英文名称: (5-aminobenzo[b]thiophene-2-yl)(morpholino)methanone
• 英文别名: [2-(4-morpholinylcarbonyl)-1-benzothien-5-yl]amine；4-(5-amino-benzo[b]thiophene-2-carbonyl)-morpholine；5-Amino-2-morpholinocarbonyl-benzothiophen；Morpholine, 4-[(5-aminobenzo[b]thien-2-yl)carbonyl]-；(5-amino-1-benzothiophen-2-yl)-morpholin-4-ylmethanone
• CAS: 832102-95-1
• 化学式: C₁₃H₁₄N₂O₂S
• mdl: MFCD16363125
• 分子量: 262.332
• InChiKey: QLLFUMWZSKLVAI-UHFFFAOYSA-N

物化性质

• 沸点：
  513.9±50.0 °C(Predicted)
• 密度：
  1.370±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  83.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5-氨基苯并[b]噻吩-2-基)-4-吗啉甲酮 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 生成 2-(吗啉-4-基甲基)-1-苯并噻吩-5-胺
  参考文献：
  名称：

  6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist

  摘要：

  Genetic manipulation studies in mice at both the MCH receptor 1 (MCHR1) as well as the MCH peptide levels have implicated MCHR1 as a key player in energy homeostasis. The phenotype exhibited by these studies, that is, increased metabolic rate, resistance to high fat diet, and subsequent weight loss, has spurred considerable efforts to develop antagonists of MCHR1. In continuation of efforts directed toward this goal, the present work capitalizes on the putative binding mode of an MCH antagonist, resulting in the identification of several novel chemotypes that are potent and selective MCHR1 antagonists. In addition, the favorable pharmacokinetics of representative examples has allowed for the evaluation of an MCHR1 antagonist in a high fat diet-induced obese rodent model of obesity. The tolerability of the right-hand side of the template for diverse chemotypes accompanied by favorable effects on weight loss enhances the attractiveness of this template in the pursuit toward development of effective anti-obesity agents.

  DOI：

  10.1021/jm060814b
• 作为产物：
  描述：

  2-氯-5-硝基苯甲醛 在 Pd/C 氢氧化钾 、 lithium hydroxide 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、275.79 kPa 条件下， 反应 37.0h， 生成 (5-氨基苯并[b]噻吩-2-基)-4-吗啉甲酮
  参考文献：
  名称：

  6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist

  摘要：

  Genetic manipulation studies in mice at both the MCH receptor 1 (MCHR1) as well as the MCH peptide levels have implicated MCHR1 as a key player in energy homeostasis. The phenotype exhibited by these studies, that is, increased metabolic rate, resistance to high fat diet, and subsequent weight loss, has spurred considerable efforts to develop antagonists of MCHR1. In continuation of efforts directed toward this goal, the present work capitalizes on the putative binding mode of an MCH antagonist, resulting in the identification of several novel chemotypes that are potent and selective MCHR1 antagonists. In addition, the favorable pharmacokinetics of representative examples has allowed for the evaluation of an MCHR1 antagonist in a high fat diet-induced obese rodent model of obesity. The tolerability of the right-hand side of the template for diverse chemotypes accompanied by favorable effects on weight loss enhances the attractiveness of this template in the pursuit toward development of effective anti-obesity agents.

  DOI：

  10.1021/jm060814b

文献信息

• NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：The Industry & Academic Cooperation in Chungnam National University (IAC)

  公开号：EP3176163B1

  公开（公告）日：2019-04-17
• Benzo[b]thiophene Derivatives. IV.¹ The Preparation and Pharmacological Activity of Compounds Related to Serotonin and Gramine
  作者：J. J. Lewis、M. Martin-Smith、T. C. Muir、S. N. Nanjappa、S. T. Reid

  DOI：10.1021/jm00342a018

  日期：1963.11
• [EN] HETEROCYCLIC MCHR1 ANTAGONISTS<br/>[FR] ANTAGONISTES HETEROCYCLIQUES DE MCHR1
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004092181A9

  公开（公告）日：2005-01-27

  [EN] This invention relates to novel heterocycles which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), also referred to as 11CBy, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines. Compounds of the invention have formula (I).
  [FR] L'invention concerne des dérivés de benzopyrane substitués, des stéréoisomères et des sels pharmaceutiquement acceptables desdits composés, ainsi que des procédés appropriés pour les préparer. Les composés de la présente invention s'utilisent comme agonistes du récepteur beta des oestrogènes. De tels agonistes s'utilisent dans le traitement d'affections induites par le récepteur beta des oestrogènes, telles que le cancer de la prostate ou l'hyperplasie prostatique bénigne (HPB).
• [EN] NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT<br/>[FR] NOUVEAU DERIVE D'INDENE, SON PROCEDE DE PREPARATION, ET COMPOSITION PHARMACEUTIQUE POUR LA PREVENTION OU LE TRAITEMENT DE MALADIES RETINIENNES EN CONTENANT COMME PRINCIPE ACTIF<br/>[KO] 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
  申请人：IAC IN NAT UNIV CHUNGNAM

  公开号：WO2016017980A1

  公开（公告）日：2016-02-04

  본 발명은 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물에 관한 것으로, 본 발명에 따른 신규한 인덴 유도체, 이의 광학 이성질체, 또는 이의 약학적으로 허용가능한 염은 RIPK1(Receptor-interacting serine/threonine-protein kinase 1)의 억제 효과가 뛰어나므로, 이를 유효성분으로 함유하는 조성물은 색소성 망막염 (RP), 레베르 선천 흑암시(LCA), 스타가르트병, 어셔증후군, 맥락막 결여, 로드-콘 또는 콘-로드 디스트로피, 섬모병증, 미토콘드리아 장애, 진행성 망막 위축증, 퇴행성 망막 질환, 노화 관련된 황반 변성(AMD), 습성 AMD, 건성 AMD, 지도상 위축증, 가족형 또는 획득 황반병증, 망막 광수용체 질환, 망막 색소 상피-계 질환, 당뇨병성 망막증, 낭포성 황반 부종, 포도막염, 망막박리, 외상성 망막 손상, 의원성 망막 손상, 황반 원공, 황반 모세관확장증, 신경절 세포 질환, 시신경 세포 질환, 녹내장, 시신경병증, 허혈성 망막 질환, 미숙아 망막증, 망막 혈관 폐색, 가족형 마크로아뉴리즘, 망막 혈관 질환, 안혈관 질환, 녹내장으로 인한 망막신경세포 퇴화, 또는 허혈성 시신경병증 등의 망막 질환의 예방 또는 치료용 약학적 조성물로 유용하게 사용될 수 있다.